

CURRICULUM VITAE

PERSONAL DATA

Name: Evan Todd Keller, D.V.M., Ph.D., M.P.V.M.

EDUCATION

1983 University of California-Davis, Davis, California; B.S. (Veterinary Science)
1985 University of California-Davis, Davis, California; D.V.M. (Veterinary Medicine)
1985 University of California-Davis, Davis, California; M.P.V.M. (Masters Preventive Veterinary Medicine-Epidemiology)
1996 University of Wisconsin-Madison, Madison Wisconsin; Ph.D. (Developmental Biology)

RESIDENCY TRAINING

1990-1992 University of Wisconsin-Madison, Madison, Wisconsin (Veterinary Oncology)

POSTDOCTORAL TRAINING

1992-1995 National Institutes of Health Post-doctoral Fellow, University of Wisconsin-Madison, Madison, Wisconsin (Molecular Endocrinology)

ACADEMIC APPOINTMENTS

1992-1994 Epidemiologist, Bernese Mountain Dog Cancer Study
1995-1996 Assistant Research Scientist, University of Wisconsin-Madison
1996-1998 Assistant Professor, Medicine and Pathology, Eastern Virginia Medical School
1996-1998 Director of Laboratory, Glennan Center for Geriatrics
1998-2001 Assistant Professor of Comparative Medicine, Unit for Laboratory Animal Medicine, University of Michigan Medical School
1998-2001 Assistant Professor of Pathology, Dept. of Pathology, University of Michigan Medical School
1999-2003 Assistant Research Scientist, Institute of Gerontology, University of Michigan
1999-present Honorary Professor, Dept. of Immunology, Tianjin Medical University, Tianjin, China
2001-present Associate Professor, Dept. of Pathology and Unit for Laboratory Animal Medicine, University of Michigan Medical School
2003-present Research Associate Professor, Institute of Gerontology, University of Michigan
2004-present Associate Professor, Dept. of Urology, University of Michigan Medical School

CONSULTING POSITIONS

1997 K. Kregel, PI. University of Iowa. RO1 NIA, "Oxidative Stress and Aging: Integrated Mechanisms."
1999-2000 Parke-Davis (now Pfizer) Pharmaceuticals, Bone biology.
2002-current Centocor
2002-current Amgen
2003-current MedeaCorp
2003 Vertex Pharmaceuticals
2003-current Northwest Airlines
2004 Eisai pharmaceuticals
2004-2005 Pfizer

SCIENTIFIC ACTIVITIES

Journals

1994 -present Ad hoc reviewer, *Journal Veterinary Internal Medicine*
1995 -present Ad hoc reviewer, *Journal of Gerontology: Biological Sciences*
1996 - 1999 Deputy Editor, *Journal of Gerontology: Medical Sciences*
1996 Ad hoc reviewer, *Life Sciences*
1996 Ad hoc reviewer, *Oncology*
1998-present Ad hoc reviewer, *Cancer Research*
1999 Ad hoc reviewer, *Cytokine*
1999 Deputy Editor, *Journal of Gerontology: Medical Sciences*
2000-present Ad hoc reviewer, *Hormone and Metabolic Research*
2000-present Ad hoc reviewer, *Urology*
2001-present Ad hoc reviewer, *The Prostate*
2001-present Ad hoc reviewer, *Journal of Clinical Investigation*
2001-present Ad hoc reviewer, *Clinical Cancer Research*
2002-present Ad hoc reviewer, *Neoplasia*
2002 Ad hoc reviewer, *Journal of Veterinary Internal Medicine*
2002 Ad hoc reviewer, *Veterinary Medicine*
2003-present Ad hoc reviewer, *Molecular Cancer Research*
2003-present Ad hoc reviewer, *Journal Bone Mineral Research*
2004 Ad hoc reviewer, *Acta Pharmacologica Sinica*
2004 Ad hoc reviewer, *International Journal of Cancer*
2004 Ad hoc reviewer, *Journal of Urology*

Grant Reviews

1997-present External Scientific Grant Reviewer, VA Merit Review Board, Department of Veterans Affairs
1997-present Ad hoc reviewer, U.S. Army Osteoporosis Grants
1997 Ad hoc reviewer, EVMS Institutional Grants
1998-present American Federation for Aging Research
2000 Office of Vice President for Research, U.M.
2000 NIH: Special Emphasis Panel, NIA Claude Pepper Center Reviews
2001 NIH: NIAAA: Special Emphasis Panel, Microarray based research on alcohol's effects on behavior, nervous system function and organ pathophysiology.
2001-present Department of Defense Section C Review Panel: Osteoporosis Grants
2001 NIH: Caloric restriction Special Emphasis Panel
2001 American Kennel Club Canine Research Grants
2001-present Department of Defense Pathology B: Prostate Cancer Grants
2002-present NIA: Program Project Reviews
2002 Ohio Cancer Research Foundation
2003- NIH: Comparative Biology of Aging Special Emphasis Panel
2004 NIH, SIBR Cancer Therapy
10/2004 Standing Member of Tumor microenvironment (TME) study section of Center for Scientific Review (CSR)/NIH

Meeting Organization

1998 Chair: Bone biology section: Serono Symposium on Menopause, Newport Beach, CA.
2002 Organization Committee: Biology of Aging Symposia. The second international conference on aging and geriatrics. Washington DC.
2002 Chair, Basic Biology of Aging Symposia at the second international conference on aging and geriatrics. Washington DC.
2003 Organizer, Connective Tissue Oncology Symposia, University of Michigan
2004 Discussion Leader, Nathan Shock Center Meeting on Animal Models of Aging,

	University of Michigan.
2004	Chair, Prostate Cancer Session, 9 th World Congress on Advanced in Oncology, Crete, Greece.
2004	Chair, Bone Metastasis Session, Prouts Neck Prostate Cancer Conference, Prouts Neck, ME.
2005	Chair, Bone Metastasis Session, InterProstate SPORE meeting, Houston, TX.
<i>U. Michigan</i>	
1999-current	Director, Bone metabolism core, Program in Comparative Integrative Genomics
1999-current	Member, Michigan Comprehensive Cancer Center
1999-current	Faculty, Graduate Program in Cellular and Molecular Biology
1999-current	Faculty, Graduate Program in Immunology
1999-current	Member, Multipurpose Arthritis and Musculoskeletal Disease Center
1999-2004	Director, NCCR Training Grant on Training Veterinarians as Biomedical Scientists
2000-current	Co-Director, Program in Connective Tissue Oncology, U.M. Cancer Center
2000-current	Director, Nathan Shock Center Mutant & Transgenic Rodent Core

GRANT SUPPORT

Recent

- University of Wisconsin School of Veterinary Medicine Companion Animal Fund. "Particle-bombardment gene therapy in the dog." (MacEwen, PI; Keller Co-PI), 1992 (\$20,000 total).
- American Federation for Aging Research (A96169) "Androgen's Effect on Interleukin-6 Expression in Bone Cell Lines." (Keller; PI), 7/1/96-6/30/97 (\$40,000 total).
- Virginia Center on Aging, "Do free radicals induce interleukin-6 expression in the rat hippocampus? A model for Alzheimer's disease." (Keller; PI) 6/97-5/98, (\$16,500 total).
- National Institutes of Health (RO1-AG-11970-Supplement). "Minority supplement to the parent grant: Interleukin-6 and Osteoporosis." (Keller; Role: PI) 5/1/97-4/30/98. (\$50,000 annual direct costs).
- National Institute of Aging (R01-AG-11970), "Interleukin-6 and Osteoporosis" (Keller; PI), 5/1/95-4/30/01 (\$228,827 annual direct cost).
- U. Michigan Cancer (Center Summer Student Research Grant) "Role of interleukin-6 in prostate cancer bone metastases." (Keller:PI; Dai Student) 06/01/99-08/31/99, (\$2,500).
- U. Michigan BMRC (Equipment Grant). Light Cycler PCR Machine (Keller; Role: PI). 04/01/00 (\$48,175 annual direct cost).
- Parke-Davis Pharmaceuticals, (Gift)(Keller: PI) "For Bone Biology Research Development" , 10/01/99-current (\$50,000).
- U. Michigan SPORE in Prostate Cancer. "Role of AKT kinase in androgen-independent prostate cancer, Z. Fu Student Award. (Keller; Role: PI Mentor) 08/01/00-07/31/01 (\$5,000 annual direct costs).
- U. Michigan SPORE in Prostate Cancer. "Role of osteoprotegerin in prostate cancer, J. Zhang Student Award. (Keller; Role: PI Mentor) 08/01/00-07/31/01 (\$5,000 annual direct costs).
- U. Michigan SPORE in Prostate Cancer Summer Student Award (Student: Mary Whitney) (Keller Role: PI Mentor) \$5,000.
- U. Michigan SPORE in Prostate Cancer Summer Student Award (Student: Zheng Fu) (Keller Role: PI Mentor) \$5,000.
- UROP Summer Student Award (Student: Mary Whitney) (Keller Role: PI Mentor) \$2,500.
- National Institute of Aging (R01-AG-15904), Supplement for "Ethanol-mediated osteoporosis and interleukin-6." (Keller, PI) 12/15/98-12/14/01 (\$61,000 annual direct cost).
- National Cancer Institute. SPORE in Prostate Cancer. "Inhibition of interleukin-6 to enhance

prostate cancer chemotherapy.” (Keller, PI), 10/01/99-9/28/00. (\$45,000 annual direct cost).

National Institute of Aging (R01-AG-15904), “Ethanol-mediated osteoporosis and interleukin-6.” (Keller, PI) 3/1/98-2/28/03 (\$148,000 annual direct cost).

U. Michigan BMRC (Basic Science Program Project Planning Grant) “The biology of prostate cancer skeletal metastases.” (Keller; Role: PI), 10/01/99-04/30/01 (\$10,000 annual direct cost).

Immunex (Gift) (Keller: PI) “For prostate cancer bone metastases research” 10/01 (\$40,000).

Department of Defense. (DAMD17-00-1-053) “Interleukin-6 and prostate cancer progression.” (Keller, PI) 06/01/00-05/30/03 (\$69,000 annual direct cost).

National Institute of Aging. (R01-AG-15884) “Aging, gene expression and oxidative stress” (Keller; PI) 12/01/99-11/30/02 (\$170,000 annual direct cost).

National Center for Research Resources. (T32 RR-07008-21) “Biomedical Research Training for Veterinary Scientists.” (Keller, PI) through-1/30/04 (\$260,000 annual direct cost)

CapCURE Foundation (Keller: PI 1/02 (\$75,000) “Targeting prostate cancer bone metastases”

Stuart and Barbara Padnos Endowed Research Fund of the University of Michigan Comprehensive Cancer Center “A prostate cancer metastasis suppressor gene” (Keller:PI) 05/02-04/03 (\$50,000)

Active

National Institute of Aging (R01-AG-21866) (Keller, PI) “Development of Mature Zebrafish as an Animal Model.” 06/01/02—05/30/07 (\$250,000 annual direct cost.)

National Cancer Institute (P30-CA-46592), (M. Wicha, P.I.; Keller, Associate Director of Connective Tissue Oncology Program) 6/1/96 - 5/31/01. (\$1,865,046 total grant annual directs)

National Institute on Aging. (P30-AG-13283) “Nathan Shock Center, Biology of Aging.” (J. Faulkner, PI; Keller, Director Mutant and Transgenic Rodent Core) 07/01/00-06/30/05. (\$84,889 Core Annual Directs).

National cancer Institute (P50-CA69568) (K. Pienta, Program PI; E. Keller Project PI) SPORE in Prostate Cancer. Keller’s Project: The role of bone resorption in prostate cancer skeletal metastases. (7/01/03-7/13/08) \$160,000 annual direct costs.

Department of Defense (DAMD17-03-1-0092) (Keller, PI) “Targeting Osteoclastogenesis in Prostate Cancer Skeletal Metastasis” 02/01/03-001/31/05 (\$330,000 Total Costs).

National Cancer Institute (R01 CA103109) (Keller, PI) VEGF and bone remodeling in skeletal metastases. (11/01/03-10/31/06) \$225,000 annual directs.

Centocor Research contract (Keller, PI) “Targeting interleukin-6 in prostate cancer progression” (9/01/03-8/31-04) \$230,000 total.

National Cancer Institute (P01CA093900) (E. Keller, Program PI) The biology of prostate cancer skeletal metastases. \$1,004,000 annual direct cost. (6/01/04-5/30/09) \$8,000,000 TOTAL Costs THIS IS A PROGRAM PROJECT.

National Cancer Institute (R01CA098513) (E. Keller, PI) Prostate Cancer Metastasis Suppressor: Role of RKIP. (3/01/04-2/28/09) \$162,000 annual direct costs.

Pending

NIH (L. Baker, PI) (Keller, CoI). PDGF-R expression and inhibition in skeletal metastases. \$175,000 annual directs.

NIH (Keller, PI) Interleukin-6 & androgen refractory prostate cancer. \$200,000 annual directs.

NIH (E. Feldman, PI) (Keller, CoI). IGF-I receptor is a therapeutic target in neuroblastoma. \$250,000 annual directs.

American Kennel Club (Keller, PI). Mapping genes associated with osteosarcoma in large dog breeds. \$141,770 annual directs.

Department of Defense (Keller, PI). Defining mechanisms through which raf kinase inhibitor protein (RKIP) suppresses metastasis in prostate cancer. \$125,000 annual directs.

CERTIFICATION AND LICENSURE

- 1985 Licensed to practice veterinary medicine, #9123, California
- 1990 Licensed to practice veterinary medicine, #3520, Wisconsin
- 1993 Board Certification: American College of Veterinary Internal Medicine Subspecialty: Oncology
- 2001 Licensed to practice veterinary medicine, #6901008777, Michigan

MILITARY SERVICE

None

HONORS AND AWARDS

- 1994 Smith-Kline Beecham Outstanding Oral Presentation Award. American College of Veterinary Internal Medicine Annual Meeting, San Francisco, CA.
- 1995 Finalist, George Sacher Award for outstanding abstract. Geriatric Society of America Annual Meeting, Los Angeles, CA.
- 1995 Agracetus, Inc., Collaborator Travel Award. Middleton, WI.
- 1996 Mentored Dave Hall; Outstanding Abstract Award for Paper Presentation: Eastern Virginia Medical School Annual Research Conference.
- 1996 Mentored Jian Zhang; Annual Meeting Poster Award for Outstanding Geriatrics Research in Physiology, Cellular and Molecular Biology for the poster. American Geriatric Society annual meeting. Chicago, IL.
- 1996 John A. Hartford Foundation Student Travel Award. The American Geriatric Society/American Federation for Aging Research Annual Meeting. Chicago, IL.
- 1996 New Investigator Award for Outstanding Achievement in Biological Aging Research. Institute on Aging, 8th Annual Colloquium. University of Wisconsin-Madison, WI.
- 1997 Mentored Jian Zhang; Young Investigator Award. Oxygen Society Annual Meeting, San Francisco, CA.
- 1997 Mentored Dave Hall; Finalist for the George Sacher Award. Gerontological Society of America Annual Meeting, Cincinnati, OH.
- 1997 Mentored Dave Hall; Platform Presentation: Eastern Virginia Medical School Annual Research Conference.
- 1997 Permanent Membership to the Frontiers of Bioscience Society of Scientists.
- 1998 Merck US Human Health/American Geriatrics Society New Investigator award. American Geriatrics Society, Seattle, WA.
- 1999 Appointed Honorary Professor of Immunology, Tianjin Medical University, Tianjin China.
- 1999 Outstanding Paper Presentation, International Osteoporosis Society, Xian, China
- 1999 Presidential Poster Award, American Geriatric Society Annual Meeting
- 2000 Visiting Professorship, Dept. of Immunology, Tianjin Medical University, Tianjin China.
- 2000 Abstract selected for Plenary Poster Session, American Society Bone and Mineral Research Annual Meeting, Toronto.
- 2001 CaPCURE prostate cancer research award

MEMBERSHIP IN PROFESSIONAL SOCIETIES

American Association for the Advancement of Science
American Association of Cancer Research
American College of Veterinary Internal Medicine

American Geriatric Society
American Veterinary Medical Association
International Bone and Mineral Society
New York Academy of Sciences
Oxygen Society
The Gerontological Society of America
Veterinary Cancer Society
Endocrine Society
Chinese Hard Tissue Society
Chinese Cancer Society

TEACHING ACTIVITIES

2000-2002 PIBS Admissions Committee Immunology Representative

Courses:

Didactic:

Course: Cell Molecular Biology 580, U. Michigan, 1999.

Lecture: Oxidative stress-mediated induction of gene expression.

Educational Goals: Detail mechanism through which oxidative stress induces gene expression.

Effort: 1 hour contact time.

Course: Pathology 580, U. Michigan, 1999.

Lectures: The biology of oxidative stress.

Educational Goals: Describe the basic biology of oxidative stress, how oxidative stress mediates damage, and induces signal transduction.

Effort 6 hours contact time.

Course: Advanced tumor biology, EVMS, 1997.

Lecture: Anticancer molecular therapeutics.

Educational Goals: Detail gene therapy strategies including methods of vector construction and methods of gene transfer (viral, mechanical, chemical, electrical). Detail methods of antisense technology.

Describe experimental and clinical examples of antisense and gene therapy.

Effort: 1.5 hours contact time.

Course: Immunology Journal Club, EVMS, 1997

Educational Goals: Expose students to current literature in immunology, including tumor immunology, and develop critical reviewing skills.

Effort: 1 hour of contact time

Course: Geriatrics Curriculum, EVMS, 1997

Lectures: Biology of aging

Educational Goals: Provide an overview of the theories of aging, including oxidative stress, telomeres, and cellular senescence.

Effort: 12 hours contact time.

Course: Environmental Toxicology, U. Wisconsin, 1995

Lecture: Tumor immunology

Educational Goals: Detail basic tumor immunology including cytotoxic T-cell, natural killer cell, and tumor specific antigen biology.

Effort: 2 hour contact time.

Course: Nutrition, U. Wisconsin, 1995
Lecture: Aging and immunology
Educational Goals: Describe how the immune system changes with aging.
Effort: 1 hour contact time.

Course: Advanced Internal Medicine Review, U. Wisconsin, 1993
Lecture: Overview of genetics
Educational Goals: Provide review of Mendelian genetics and introduce basic concepts of molecular genetics.
Effort: 1 hour contact time.

Course: Oncology, U. Wisconsin, 1992
Lectures: Hemostasis disorders
Educational Goals: Instruct students on clinical presentation, diagnosis and treatment of bleeding disorders
Effort: 2 hours contact time

Course: Advanced Internal Medicine Review, U. Wisconsin, 1992
Lecture: Principles of immunodiagnostics
Educational Goals: Provide overview of principles and practice of immunodiagnostic tests including, ELISAs, hemagglutination inhibition, and radial immunodiffusion assays.
Effort: 1 hour contact time.

Course: Advanced Internal Medicine Review, U. Wisconsin, 1991
Lecture: Disorders of calcium homeostasis
Educational Goals: Describe pathophysiology of the hormonal axis that regulates calcium regulation.
Effort: 1 hour contact time.

Clinical: All at the School of Veterinary Medicine; U. Wisconsin.
Course: Medical rounds senior veterinary students; Fall 1991 through Spring 1993
Educational Goals: Case management, Pathophysiology, Therapeutic options
Effort: 2.5 hours daily

Course: Oncology journal club; Fall 1991 through Spring 1993
Educational Goals: Expose senior students to current literature on clinical and basic research.
Effort: 1 hour weekly

<u>Student</u>	<u>Level in Lab</u>	<u>Research Area</u>	<u>Period</u>	<u>Current Level</u>
Jerdine Tan	UROP	Prostate cancer	2001-2002	UM Undergraduate
Celimar Rodriguez	UROP	Prostate cancer	2001-2002	UM Undergraduate
Fadeel Mahmood	UROP	Prostate cancer	2001-2002	UM Undergraduate
Jeff Fielhauer	UROP	Prostate cancer	2001-2002	UM Undergraduate
Neel Patel	UROP	Prostate cancer	2001-2002	UM Undergraduate
Rachel Roberts	UROP	Prostate cancer	Winter 2001	UM Undergraduate
Bianca Gruber	UROP	Prostate cancer	2001-2002	UM Undergraduate
Stephanie Bailey	UROP	Prostate cancer	Winter 2001	UM Undergraduate
Jennifer Rai	UROP	Prostate cancer	Winter 2001	UM Undergraduate
Monica Mahesh	UROP	Prostate cancer	Winter 2001	UM Undergraduate
Kara DeBoer	UROP	Prostate cancer	Winter 2000	UM Undergraduate
Mary Whitney	UROP	Prostate cancer	Winter 2000	UM Undergraduate
Bobbi Terelli	UROP	Prostate cancer	Winter 2000	UM Undergraduate
Brian Adams	Undergraduate	Heat shock prot.	Winter 2000	UM Undergraduate
Bora Hong	Undergraduate	Prostate Cancer	Fall 2000	Duke U. Undergraduate
Avni Patel	Undergraduate	Bone Cancer	Fall 2000	UM Undergraduate
Radhika Devalaraja	Post-Doctoral	Bone Disease	2000-Current	Pfizer/UM Post-Doctoral
Richard Prebish	Undergraduate	General Training	2000-Current	UM Undergraduate
Eric Diez	Undergraduate	General Training	1999-2000	UM Undergraduate
Rachel Ershler	Undergraduate	General Training	1999	UM Undergraduate
Pete Smith	Post-Doctoral	Prostate Cancer	1999-2002	Assistant Professor, Yale U.
Jill Murtha	Pre-Doctoral	Oxidative Stress	PhD 2003	Research Investigator, U.M.
Jin-lu Dai	Post-Doctoral	Bone Disease	1999-Current	Research Investigator, U.M.
Zheng Fu	Pre-Doctoral	Prostate Cancer	PhD 2002	Post-doc, Mayo Clinic
Jian Zhang	Pre-Doctoral	Oxidative Stress	PhD 2001	Assistant Professor, U. of Pittsburgh
Cristine Hart	Pre-Doctoral	Gerontology	1996-1998	Graduate Student Eastern Virginia Medical School
David Hall	Postdoctoral	Oxidative Stress	1996-1998	Research Scientist, Univ. of Iowa
Allen Michael	Postdoctoral	Bone Disease	1996-1998	Research Fellow, Univ. of Wisconsin
Shawn Parnell	Med Student	Prostate Cancer	1998	Medical School
Rebecca Lipsey	Med Student	Prostate Cancer	1998	Medical School
Patrick Lester	Post-Doc	Prostate Cancer	2002-2003	Research Fellow, ULAM
Meghan Brennan	Pre-Doctoral	Prostate Cancer	2002-current	UM Graduate Student (Pathology)
Lauren Wallner	Undergraduate	Prostate Cancer	2003-current	UM Undergraduate
Lindsey Dehne	Pre-Doctoral	Prostate Cancer	2002-2003	Undergrad

Course: Veterinary Clinical Oncology Laboratory; 1992, 1993

Educational Goals: Instruct junior students on principles and practice of clinical oncology methods including bone marrow aspiration and biopsy techniques.

Effort 6 hours yearly

Training Grants:

- 1999-current Biomedical Research Training for Veterinary Scientists Training Grant
- 1999-current Nathan Shock Center Training Grant
- 1999-current Immunology Training Program
- 1999-current Cellular and Molecular Biology Training Program
- 1999-current Urology Training Program
- 2000-current Clinical Cancer Immunology Training Grant

Summary of Keller Students:

Graduate Student Committees other than Keller's Students:

- 2000 Hen-Li Chen; Mentor Laurie McCauley; University of Michigan Dental School, PhD
 2000 Maya Williams, Mentor Kathleen Collins; Cellular Molecular Biology
 2003 Keni Gu, Mentor: Bruce Rutherford, Dental School, PhD
 2003 Mentor, Mark Day,
 2003 Michael Fridman, Mentor: Kurt Hankenson, CMB

Student's Awards:

- 1996 Dave Hall; Outstanding Abstract Award for Paper Presentation: Eastern Virginia Medical School Annual Research Conference.
 1996 Jian Zhang; Annual Meeting Poster Award for Outstanding Geriatrics Research in Physiology, Cellular and Molecular Biology. Am. Geriatric Society annual meeting. Chicago, IL
 1997 Jian Zhang; Young Investigator Award. Oxygen Society Annual Meeting, San Francisco, CA.
 1997 Dave Hall; Finalist for the George Sacher Award. Gerontological Society of America Annual Meeting, Cincinnati, OH.
 1997 Dave Hall; Platform Presentation: Eastern Virginia Medical School Annual Research Conference.
 1998 Rebecca Lipsey, EVMS Student Assistantship in Oncology. "Oxidative stress-mediated induction of interleukin-6 in prostate cells"
 1998 Shawn Parnell, EVMS Student Assistantship in Oncology. "The mechanism of androgen-mediated maintenance of I κ B α in prostate cancer cells."
 1998 Jian Zhang; Old Dominion University/EVMS Summer Student Research Grant. "Oxidative stress-mediated induction of interleukin-6 in prostate cancer cells."
 1999 JinLu Dai; U. Michigan Cancer Center Summer Student Research Grant. "Role of interleukin-6 in prostate cancer bone metastases."
 2000 Jian Zhang; U. Michigan SPORE in Prostate Cancer. "Role of osteoprotegerin in prostate cancer, J. Zhang" Student Grant.
 2000 Zheng Fu: U. Michigan SPORE in Prostate Cancer. "Role of AKT kinase in androgen-independent prostate cancer", Student Grant
 2000 J. Zhang: Plenary Poster, Am Soc Bone Min Res. Annual Meeting. "Osteoprotegerin (OPG) and anti-interleukin-6 (IL-6) antibody inhibit osteoclastogenesis induced by prostate cancer cells in vitro."
 2001 Zheng Fu: Paper presentation, Am Assoc Cancer Res. Annual Meeting. "Identification of Raf Kinase Inhibitor Protein (RKIP) as a metastasis suppressor gene in prostate cancer skeletal metastasis."
 2001 Zheng Fu: Rachkham Travel Award
 2001 Mary Whitney: UROP Summer Student Fellowship
 2001 Mary Whitney: SPORE in Prostate Cancer, Summer Research Award
 2001 Zheng Fu: SPORE in Prostate Cancer, Summer Research Award
 2003 Jian Zhang: AACR Young Investigator Award.
 2004 Zheng Fu: Poster recognized for Poster Discussion Session.

INVITED PRESENTATIONS

- "Gene therapy of cancer" invited seminar, American College of Veterinary Internal Medicine 12th Annual Meeting; San Francisco, CA, May, 1994.
 "Dihydrotestosterone inhibits interleukin-6 promoter activation," invited seminar, Geriatric Society of America Annual Meeting, Los Angeles, Nov., 1995.
 "Androgens, interleukin-6 and osteoporosis", invited seminar, First Annual Conference on Immunology and Aging; National Institutes of Health Campus, June, 1996.
 "Ethanol activation of the interleukin-6 promoter in bone marrow stromal cells," invited seminar, Geriatric Society of America Annual Meeting; Washington, DC. Nov., 1996.
 "Steroid regulation of IL-6," invited seminar, Gerontology Research Center, NIA, Baltimore, MD, Jan., 1997.
 "Hormones and IL-6," invited seminar, The Diabetes Institutes, Norfolk, VA, Jan., 1997.

- “Androgen regulation of IL-6 expression,” invited seminar, Dept. of Microbiology and Immunology, EVMS, Feb., 1997.
- “TNF represses androgen responsiveness in LNCaP prostate cancer cells,” invited seminar, Virginia Prostate Center, March 1998.
- “Aging and Gene Expression,” invited seminar, Department of Biochemistry, George Washington University, March 1998.
- “Aging and Gene Expression” invited seminar, Unit for Laboratory Animal Medicine and the Department of Pathology, University of Michigan. April, 1998.
- “IL-6: From lab bench to clinics,” invited seminar, Dept. of Veterinary Clinical Sciences, The Ohio State U. April, 1998.
- “Regulation of Interleukin-6: Expression in aging bone and brain,” invited seminar, Parke-Davis Pharmaceutical, Oct., 1998.
- “Cytokines and Prostate Cancer” invited seminar, Ann Arbor VA GRECC, Jan., 1999.
- “Crosstalk between cytokines and androgen receptor” UM SPORE in Prostate Cancer, Feb, 1999.
- “Osteoporosis and interleukin-6” invited paper, 3rd International Conference on Osteoporosis, Xian, China, April, 1999.
- “Osteoporosis and interleukin-6” invited seminar, Tianjin Medical University, Tianjin, China, April, 1999.
- “The monkey model of osteoporosis,” invited seminar, Tianjin Geriatric Institute, Tianjin, China, April 1999.
- “Interleukin-6 and prostate cancer,” invited seminar, Tianjin Cancer Institute, Tianjin, China, April 1999.
- “Oxidative stress-mediated regulation of interleukin-6 expression,” invited seminar, Dept. of Physiology, UM, June 1999.
- “The role of interleukin-6 in prostate cancer pathophysiology,” invited seminar. Michigan Consortium on Prostate Cancer Research, UM, March 2000.
- “Alcohol-mediated bone loss and interleukin-6,” invited seminar. Oral Health Sciences Seminar, School of Dentistry, University of Michigan, April 2000.
- “Cross-talk between interleukin-6 and the androgen receptor,” invited seminar. East Medical University, Shanghai, China, June 2000.
- “Cross-talk between interleukin-6 and the androgen receptor.” Invited seminar. Zhongshan Medical University, Guangzhou, China, June 2000.
- “Skeletal Metastasis in Prostate Cancer.” Invited seminar. Dept. of Urology. Kanazawa University, Japan, October 2000.”
- “Skeletal Metastasis in Prostate Cancer.” Invited seminar. Dept. of Immunology. Tianjin Medical University, Tianjin, China, October 2000.”
- “Aging and cytokines.” Invited seminar. Vaccines 2000 International Conference. Institute of Advanced Studies Geriatrics and Gerontology. Washington, D.C., October, 2000.
- “Inflammatory cytokines.” Invited seminar. Anemia in Geriatrics Summit Meeting. Sponsored by Amgen. Puerto Rico. February 2001.
- “The Biology of Skeletal Metastases” Invited seminar. Eastern Virginia Medical School, Norfolk, VA. March 2001.
- “The Biology of Skeletal Metastases” Invited seminar. American College of Veterinary Internal Medicine. Denver, CO, May 2001.
- “Prostate Cancer Skeletal Metastasis: Gene Array Analysis and Murine Models.” Invited Seminar. Midwestern Bone Biology and Cancer Meeting, Indiana University, Bloomington, IN. May 2001.
- “Targeting Prostate Cancer Skeletal Metastasis.” Invited Seminar. Immunex Corporation. Seattle, WA. June 2001.
- “Use of Gene Array to Identify A Prostate Cancer Metastasis Suppressor Gene.” Guanxi Medical University, Nanning, China. June 2001.
- “Biology of Prostate Cancer Skeletal Metastasis” Invited Seminar, Genitourinary Conference, University of Michigan, November, 2001.

- “Targeting Prostate Cancer Metastasis” Invited Seminar. University of Michigan, Nephrology Basic Science Seminar, December, 2001.
- “Biology of Prostate Cancer Metastasis” Invited seminar. Institute of Gerontology, University of Michigan, March, 2002.
- “Interleukin-6 and Prostate Cancer” Invited seminar. University of Innsbruck. Innsbruck, Austria. March 2002.
- “Prostate cancer skeletal metastasis” Invited seminar. University of Innsbruck. Innsbruck, Austria. March 2002.
- The Biology of Aging.” Invited seminar. Second International Conference on Aging. Washington, D.C. June, 2002.
- “Introduction to Cancer Metastases” Invited Seminar. 32nd International Sun Valley Hard Tissue Workshop. Sun Valley, Idaho August, 2002.
- “Applications of High Throughput Methods to Cancer Metastases” Invited Seminar. 32nd International Sun Valley Hard Tissue Workshop. Sun Valley, Idaho August, 2002.
- “The biology of prostate cancer bone metastases” Invited seminar. Mt. Sinai Hospital, New York, April 2003.
- “The biology of bone metastasis” Invited seminar. Van Andell Research Institute, Grand Rapids, Michigan, August 2003.
- “Zebrafish as a model of aging.” Conference on Aquatic Animal Models of Human Disease, Manassass, Virginia, Sept. 2003.
- “Cytokines in prostate cancer” 5th World Congress of Urology. London, England. Sept. 2003.
- “Prostate cancer-induced bone remodeling” Oral Health Sciences Seminar, U. Michigan. Oct. 2003.
- “The biology of prostate cancer skeletal metastases” 53rd Annual Meeting of the Central Division of the Japan Urological Association. Kanazawa, Japan. Nov. 2003.
- “Methuselah’s secrets: Mining the mechanisms of aging” American College of Veterinary Pathologists, Banff, Canada, Nov. 2003.
- “The biology of prostate cancer skeletal metastases” Paget’s Symposium. Houston, Texas, December 2003.
- “RKIP as a target for metastasis” Signal Transduction as a therapeutic target annual meeting. Luxembourg City, Luxembourg, January, 2004.
- “RKIP metastasis suppressor protein” Urologic Oncology Conference, U. Michigan, February 2004.
- “RKIP, a prostate cancer metastasis suppressor gene” Molecular Cancer Seminars, Medical College of Ohio, February, 2004.
- “Targeting bone metastases” EISAI Pharmaceuticals, Andover, Massachusetts, February 2004.
- “The biology of skeletal metastases” Emory University. Atlanta, Georgia, April. 2004.
- “Prostate cancer metastasis” M.D. Anderson. Houston, Texas, Sept. 2004.
- “The biology of skeletal metastases” Amgen. Seattle, WA. Sept. 2004
- “RKIP a metastasis suppressor gene” 9th World Congress on Advanced in Oncology, Crete, Greece. Oct. 2004.
- “Interleukin-6: In health and disease” Pfizer. Ann Arbor, MI Oct 2004
- “RKIP: A metastasis suppressor gene” Prouts Neck Prostate Cancer Conference, Prouts Neck, ME, November, 2004.
- “Bone morphogenetic protein-6 and osteoblastic prostate cancer metastases” InterProstate SPORE meeting, Houston, TX, January, 2005.
- “Targeting bone metastases” TEM study section, Washington, DC, February, 2005.

COMMITTEE AND ADMINISTRATIVE SERVICE

National

1995	ACVIM Oncology, Credentials Committee
1996 - present	ACVIM Oncology Residency Training Committee
1997 - present	National Scientific Advisory Council, American Federation Aging Research

1998 - present	Scientific Advisory Board, Institute for Advanced Studies in Immunology and Aging
<i>Regional</i>	
1996	University of Wisconsin Gene Therapy Working Group
1997 - 1998	Eastern Virginia Medical School Cancer Committee
1997 - 1998	Animal Care and Use Committee
1998 - present	Colony for Aged Rodents Advisory Committee
1998 - present	Comparative Integrative Genomics Operating Committee
1999 - 2001	Chair, Jody C. Ungerleider Memorial Award Committee
1999 - present	Rackham Graduate Student Appeals Committee
2000	Grant Reviewer for OVPR.
2003	Organizer, Connective Tissue Oncology Retreat

BIBLIOGRAPHY

Completed Publications in Scientific Journals

Peer-Reviewed Publications

1. Keller ET. Elevated trypsin-like immunoreactivity in a dog with exocrine pancreatic insufficiency and chronic pancreatitis. *J Am Vet Med Assoc*;196:623-626, 1990.
2. Keller ET. Testing for exocrine pancreatic insufficiency in cats. (Letter). *J Am Vet Med Assoc* 197:1112-1114, 1990.
3. Keller ET, Madewell BR. Locations and types of neoplasms in immature dogs: 69 cases (1964-1989). *J Am Vet Med Assoc* 200:1530-1532, 1992.
4. Keller ET, Vail DM. Intrapleural cisplatin as a cause of paroxysmal ventricular tachycardia. (Letter). *J Vet Int Med* 6:198-199, 1992.
5. Keller ET. Immune-mediated disease as a risk factor for canine lymphoma. *Cancer* 70:2334-2337, 1992.
6. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. *J Vet Int Med.* 7:289-295, 1993.
7. Keller ET. Gene therapy for the dog. *Veterinary Cancer Society Newsletter.* 18(1), 10-11, 1994.
8. MacEwen EG, Kurzman ID, Helfand S, Vail D, London C, Kisseberth W, Rosenthal RC, Fox LE, Keller ET, Obradovich J, Madewell B, Rodriguez C, Kitchell B, Fidel J, Susaneck S, Rosenberg M. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. *J Drug Targeting.* 2:391-396, 1994.
9. Keller ET, Ershler WB. Effect of IL-6 receptor antisense oligodeoxynucleotide in vitro proliferation of myeloma cells. *J Immunol.* 154:4091-4098, 1995.
10. Kisseberth WC, MacEwen EG, Helfand SC, Vail DM, London CL, Keller ET. Response to liposome-encapsulated doxorubicin (TLC D-99) in a dog with myeloma. *J Vet Int Med.* 9:425-428, 1995.
11. Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, Obradovich J, Fidel J, Rosenberg M. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. *Clin Cancer Res.* 1:1595-1601, 1995.
12. Padgett GA, Madewell BR, Keller ET, Jodar L, Packard M. Inheritance of histiocytosis in Bernese mountain dogs. *J Small Animal Practice.* 36:93-98, 1995.
13. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee H, Wang C, Mizokami A. Androgen receptor: An overview. *Crit Rev Euk Gene Trans.* 5:97-125, 1995.
14. Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. *Frontiers in Bioscience* 1:59-69, 1996.
15. Keller ET, Chang C, Ershler WB. Inhibition of NFkB through maintenance of Ikb levels

- contributes to dihydrotestosterone-mediated inhibition of the interleukin-6 promoter. *J Biol Chem*, 271:26267-26275, 1996.
16. Keller ET, Burkholder JK, Shi F, Pugh TD, McCabe D, MacEwen EG, Malter JS, Yang NS, Ershler WB. *In vivo* particle-mediated cytokine gene transfer into canine oral mucosa and epidermis. *Cancer Gene Therapy* 3:186-191, 1996.
 17. Keller ET, Wanagat, J, Ershler, WB. The molecular and cellular biology of interleukin-6 and the interleukin-6 receptor. *Frontiers in Bioscience*, 1:340-357, 1996. (<http://www.bioscience.org/1996/v1/d/keller2/htmls/340-357.htm>)
 18. Keller ET, Pugh TD, Sun WH, Ershler WB. Evaluation of ovariectomy and dehydroepiandrosterone sulfate administration on interleukin-6 levels and B16 melanoma growth in mice. *Age*, 19:75-81, 1996.
 19. Martinez E, Moore DD, Keller ET, Pearce D, Robinson V, Simons Jr, S, Sanchez E, Danielsen M. The Nuclear Receptor Resource Project. *Nucl Acids Res*, 25:163-165, 1997.
 20. Keller ET. Of Mice and Women, *Trends Endocrinol Metab*, 8:327-328, 1997.
 21. Keller ET, Zhang J, Ershler WB. Ethanol activates the interleukin-6 promoter in a human bone marrow stromal cell line. *J Gerontol: Biol Sci* 52A:B311-317, 1997.
 22. Ershler WB, Harman SM, Keller ET. Immunologic aspects of osteoporosis. *Develop Compar Immunol* 21:487-499, 1997.
 23. Martinez E, Moore DD, Keller ET, Pearce D, Vanden Huevel JP, Robinson V, Simons Jr, Gottlieb B, MacDonald P, Simons Jr, S, Sanchez E, Danielsen M. The nuclear receptor resource: a growing family. *Nucl Acids Res* 26:239-241, 1998.
 24. Zhang J, Pugh TD, Stebler, B, Ershler WB, Keller ET. Orchiectomy increases bone-marrow interleukin-6 levels in mice. *Calcif Tiss Int* 62:219-226, 1998.
 25. Sun WH, Keller ET, Stebler BS, Ershler WB. Estrogen inhibits phorbol ester-induced I κ B transcription and protein degradation. *Biophys Biochem Res Com*, 244:691-695, 1998.
 26. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang N-S, MacEwen EG. Development of human granulocyte-macrophage colony-stimulating factor transfected tumor cell vaccines for the treatment of spontaneous canine cancer. *Human Gene Therapy*, 9:1851-1861, 1998.
 27. Binkley N, Ellison G, O'Rourke C, Hall D, Johnston G, Kimmel D, Keller ET. A rib biopsy technique for the cortical bone evaluation in rhesus monkeys (*Macaca mulatta*). *Lab Animal Sci*, 49:87-89, 1999.
 28. Keller ET, Gravenstein SG. The Biology of Aging: Genetic and Immunologic Influences. In "Towards a Healthier Old Age", Prous Science Telesymposium, <http://www.prous.com/ts>, 1999.
 29. Chiu KM, Kiami PH, Schmidt MJ, Havighurst TC, Shug AL, Daynes RA, Keller ET, Gravenstein S. Correlation of serum L-carnitine and dehydroepiandrosterone sulfate (DHEAS) levels with age and gender in healthy adult people. *Age Ageing*, 28:211-216, 1999.
 30. Chiu KM, Keller ET, Crenshaw TD, Gravenstein S. Carnitine and dehydroepiandrosterone sulfate induce protein synthesis in porcine primary osteoblast-like cells. *Calcif Tissue Int*. 64:527-533, 1999.
 31. Keller ET, Binkley NC, Stebler BA, Hall DM, Johnston G, Zhang J, Ershler WB. Ovariectomy does not induce osteopenia through interleukin-6 in rhesus monkeys (*Maccaca mulatta*). *Bone*. 26:55-62, 2000.
 32. Chiu KM, Arnaud CD, Ju J, Mayes D, Bacchetti P, Weitz S, Keller ET. Correlation of estradiol, parathyroid hormone, interleukin-6 and interleukin-6 receptor during the normal menstrual cycle. *Bone*. 26:79-85, 2000.
 33. Knezevic-Cuca J, Stansberry KB, Johnston G, Zhang J, Keller ET, Vinik AI, Pittenger GL. Neurotrophic role of interleukin-6 and soluble interleukin-6 receptors in N1E-115 neuroblastoma cells. *J Neuroimmunol*. 102:8-16, 2000.
 34. Ershler WB, Keller ET. Age-associated increased IL-6 gene expression, late life diseases and frailty. *Ann Rev Medicine*. 51:245-270, 2000.
 35. Muenchen H, Lin DL, Walsh MA, Keller ET, Pienta KJ. TNF-induced apoptosis in prostate cancer cells through inhibition of NF- κ B by an I κ B α "Super-Repressor." *Clin Cancer Res*.

- 6:1969-1977, 2000.
36. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Tumor necrosis factor- represses androgen sensitivity in the LNCaP prostate cancer cell line. *J Urol.* 164:800-805, 2000.
 37. Dai J, Lin D, Zhang J, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through interleukin-6 in mice. *J Clin Invest.* 106:887-895, 2000.
 38. Morris MD, Tarnowski CP, Timlin A, Carden A, Dreier JL, Ignelzi MA Jr., Lin DL, Keller ET. Raman imaging as a probe of chemical and biomechanical properties of bone tissue. *Proc. SPIE,* 3918, 151-158, 2000.
 40. Smith PC, Hobish A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. *Cytokine and Growth Factor Rev.* 12:33-40, 2001.
 41. Keller ET, Zhang J, Yao Z, Qi Y. The impact of chronic estrogen deprivation on immunologic parameters in the ovariectomized rhesus monkey (*Macaca mulatta*) model of menopause. *J Repro Immunol.* 50:41-55, 2001.
 42. Yao Z, Zhang J, Dai, J, Keller ET. Ethanol activates NF κ B DNA binding and p56lck protein tyrosine kinase in human osteoblast-like cells. *Bone,* 28:167-173, 2001.
 43. Lin DL, Tarnowski CP, Patel AH, Rohn E, Morris MD, Keller ET. The bone metastatic LNCaP-derivative C4-2B prostate cancer cell line induces mineralization in vitro. *Prostate,* 47:212-221, 2001.
 44. Harada S, Keller ET, Fujimoto N, Koshida K, Namiki M, Matsumoto T, Mizokami A. Longterm exposure of tumor necrosis factor- α causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. *Prostate,* 46:319-326, 2001.
 45. Zhang J, Dai J, Smith P, Qi Y, Lin D, Strayhorn C, Mizokami A, Fu Z, and Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone of mice. *J Clin Invest,* 107:1235-1244, 2001.
 46. Zhang J, Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NF κ B and the interleukin-6 promoter requires NF κ B-inducing kinase activity. *Antioxidant Redox Signaling,* 3:493-504, 2001.
 47. Richard V, Lairmore MD, Green PL, Feuer G, Erbe RS, Albrecht B, Keller ET, Dai J, Rosol TJ. Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression. *Am J Pathology,* 158:2219-2228, 2001.
 48. Smith PC and Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. *Prostate,* 48:47-53, 2001.
 49. Lin DL, M Whitney, Z Yao, Keller ET. Interleukin-6 induces androgen receptor activity through up-regulation of receptor expression in prostate cancer cells. *Clin Cancer Res,* 7:1773-1781, 2001.
 50. Evan T. Keller, Jian Zhang, Carlton R. Cooper, Peter C. Smith, Laurie K. McCauley, Kenneth J. Pienta and Russell S. Taichman. Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. *Cancer Metastasis Reviews* 20:333-349, 2001.
 51. Fu Z, Dozmorov IM, Keller ET. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells similar to that found in bone metastatic prostate cancer cells. *Prostate,* 51:10-20, 2002.
 52. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. *Drugs Today,* 38:91-102, 2002.
 53. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. *Cancer Res,* 62: 1832-1837, 2002.
 54. Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. *J Bone Min Res* 17:1256-1263, 2002.
 55. Demiralp, B., H. Chen, A.J. Koh-Paige, E.T. Keller, and L.K. McCauley. Anabolic effects of

- parathyroid hormone during endochondral bone growth are dependent on c-fos. *Endocrinology* 143:4028-4047, 2002.
56. Stewart S, Shea DA, Tarnowski CP, Morris MD, D Wang Franceschi R, Lin DL and E Keller, Trends in early mineralization of murine calvarial osteoblastic cultures. A Raman microscopic study. *Journal of Raman Spectroscopy*. 33: 536-543, 2002.
 57. Keller ET. Overview of metastasis and metastases. *Journal of Musculoskeletal Neuronal Interactions*. 2:567-569, 2002.
 58. Keller ET, Yao Z. Applications of high-throughput methods to cancer metastases. *Journal of Musculoskeletal Neuronal Interactions*. 2:575-578, 2002.
 59. Fujita H, Koshida K, Keller ET, Takahasi Y, Yoshimoto T, Namiki M, Mizokami A. Cyclooxygenase-2 promotes prostate cancer progression. *Prostate* 53:232-240, 2002.
 60. Khorram O, Colman RJ, Kemnitz JW, Magness RR, Zhang J, Yao Z, Keller ET. The influence of sex hormones on circulating nitric oxide (NOx) levels in Rhesus monkeys (*Macaca mulatta*). *Med Sci Monit* 8:BR489-95, 2002.
 61. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ. Stromal factors involved in prostate carcinoma metastasis to the bone. *Cancer (suppl)* 97:739-747, 2003.
 62. Keller ET and J. Brown JM. Osteoprotegerin (OPG), receptor activator of NF κ B ligand (RANKL) and RANK in cancer metastasis. *Research Advances in Cancer* 3:81-93, 2003.
 63. McCauley LK, Tozum TF, Kozloff KM, Koh-Paige AJ, Chen C, Demashkieh M, Cronovixh H, Richard V, Keller ET, Rosol TJ, Goldstein SA. Transgenic models of metabolic bone disease: Impact of estrogen receptor deficiency on skeletal metabolism. *Connect Tissue Res* 44(Suppl. 1):250-263, 2003.
 64. Murtha JM, Qi W, Keller ET.. Hematologic and serum biochemical values for zebrafish (*Danio rerio*). *Comp Med* 53:37-41, 2003.
 65. Murtha JM, Qi W, Keller ET. Characterization of the Heat Shock Response in Mature Zebrafish (*Danio rerio*). *Experimental Gerontol*. 38:683-691, 2003.
 66. Fu Z, Smith PC, Zhang L, Rubin M, Dunn RL, Yao Z, Keller ET. Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis. *J Natl Cancer Inst*.95:878-889, 2003. Has accompanying editorial.
 67. Varani J, Fligiell H, Zhang J, Aslam MN, Lu Y, Dehne LA, Keller ET. Separation of retinoid-induced epidermal thickening from skin irritation. *Arch Dermatol Res*. 295:255-262, 2003.
 68. Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E. Characterization of C4-2 prostate cancer bone metastases and their response to castration. *J Bone Min Res*. 18:1882-1888, 2003.
 69. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate cancer progression in bone. *Cancer Res*. 63:7883-7890, 2003.
 70. Kacergius T, Deng Y, Keller ET. Influenza virus and gamma interferon synergistically increase nitric oxide production in RAW 264.7 and AMJ2-C11 macrophages. *Acta Medica Lituanica* 10:174-184, 2003.
 71. Lester PR, Keller ET. The comparative biology of skeletal metastasis. *Vet Comp Oncol*. 1:131-139, 2003.
 72. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. *Cancer Res*. 64:994-999, 2004.
 73. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. *J Cell Biochem*. 91:718-729, 2004.
 74. Zhang J, Lu Y, O'brien CA, Dai J, Qi W, Hall DE, Manolagas SC, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: Evidence for free radical theory of aging. *Experimental Gerontology*.39:239-247, 2004.
 75. Artz AS, Fergusson D, Drinka PJ, Gerald M, Bidenbender R, Lechich A, Silverstone F,

- McCamish MA, Dai J, Keller E and Ershler WB, Mechanisms of Unexplained Anemia in the Nursing Home. *J Am Geriatr Soc* 52:423-427, 2004.
76. Keller ET, Fu Z. Defining RKIP as a protein that regulates prostate cancer metastasis. *Am J Urolog Rev* 2:72-80, 2004. Accompanying commentary on pp 81-83.
 77. Keller ET. Signal transduction pathways as therapeutic targets. *IDrugs* 7:217-222, 2004.
 78. Zhang J, Lu Y, Kitazawa R, Kitazawa S, Dai J, Zhao X, Yao Z, Pienta KJ, Keller ET. Role of TGF- β in Prostate Cancer Skeletal Metastases: In Vivo Real-time Imaging of TGF- β -induced RANK Ligand Transcriptional Activation in Prostate Cancer. *Prostate*. 59:360-369, 2004.
 79. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagawa Y, Keller ET, Sedivy JM, Yeung KC. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. *J Biol Chem* 279:17515-17523, 2004.
 80. Keller, ET, Fu Z, Yeung K, Brennan M. Raf kinase inhibitor protein: A prostate cancer metastasis suppressor gene. *Cancer Letters* 207:131-137, 2004.
 81. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. *Cancer Res* 64:765-771, 2004.
 82. Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone JF, Aguzzi A, Ershler WB, Dai J, Fraser P, Hysloop PSG, Holtzman DM, Walker LC, Keller ET. Alzheimer A β Vaccination of Rhesus Monkeys (*Macaca mulatta*) Mech Ageing Dev 125:149-151, 2004.
 83. Chen C, Koh AJ, Datta NS, Zhang J, Keller ET, Xiao G, Franceschi RT, D'Silva NJ, McCauley LK. Impact of Mitogen-activated Protein Kinase (MAPK) Pathway on Parathyroid Hormone Related Protein Actions in Osteoblasts. *J Biol Chem* 279:29121-29129, 2004.
 84. Loberg RD, Fridman Y, Pienta B, Keller ET, McCauley L, Taichman R, Pienta KJ. Detection and isolation of circulating tumor cells in urologic cancer: A review. *Neoplasia* 6(4):302-9, 2004.
 85. Keller ET, Fu Z, Brennan M. The role of Raf kinase inhibitor protein (RKIP) in health and disease. *Biochem Pharmacol* 68(6):1049-53, 2004.
 86. Keller ET. Metastasis suppressor genes: A role for raf kinase inhibitor protein (RKIP). *Anti-cancer drugs* 15(7):663-9, 2004.
 87. Gerhard GS, Malek RL, Cheng KC, Keller ET, Murtha J. Zebrafish, killifish, neither fish, both fish? (Letter) *J Exp Gerontol* 59(9):B873-B875, 2004.
 88. Keller ET, Murtha JM. The use of mature zebrafish (*Danio rerio*) as a model for human aging and disease *Compar Biochem Physiol* 138(3): 335-341, 2004.
 89. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6. *Clin Exp Met* 21(5): 399-408, 2004.
 90. Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. *J Cell Biochem* 94(2): 273-278, 2005.
 91. Sun Y, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman N, Liang Z, Koh-Paige A, Shim H, Pienta K, Keller E, McCauley L, and Taichman RS. Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. *J Bone Min Res* 20(2): 318-329, 2005.

Articles Accepted for Publication

1. Keller ET, Hall C, Dai J and Wallner L. Biomarkers of growth, differentiation and metastasis of prostate epithelium. *J Clin Ligand Assay*.

Submitted Articles

1. Dai J, Zhang J, Qi Y, Keller ET. Precision and accuracy for determination of whole body and femoral bone mineral measurements in mice using dual-energy x-ray absorptiometry.

- (Submitted).
2. Corey E, Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL. Osteoprotegerin and Zoledronic Acid Reduce Effects Associated with C4-2 Prostate Cancer Bone Metastases. (Submitted).
 3. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LM. Increased bone turnover facilitates prostate cancer skeletal localization (submitted).

Books

1. The Biology of Bone Metastases. Keller ET. Editor, Chung L. Associate Editor. Kluwer Academic Publishers. Boston, MA. 2004.

Chapters in Books

1. MacEwen EG, Keller ET. Current strategies for management of metastatic disease. In: Kirk RW, ed. Current Veterinary Therapy XI, Philadelphia, W.B. Saunders, 427-432, 1992.
2. Cotter SM, Keller ET. Oncology. In: Pratt PW, ed. Review questions & answers for veterinary boards, Goleta, CA, American Veterinary Publications, Inc., 191-202, 1993.
3. Keller ET, Helfand SC. Soft tissue sarcomas in the cat. In: August J ed. Consultations in feline medicine. Philadelphia, W. B. Saunders, 557-566, 1994.
4. Kurzman I, Keller ET, MacEwen EG. New Developments in Cancer Therapy. In: Withrow SJ, MacEwen EG, eds, Clinical Veterinary Oncology. 2nd ed. Philadelphia. W.B. Saunders, 147-166, 1995.
5. Keller ET. Mechanisms of bone resorption in prostate cancer skeletal metastases. In: Lucas, JN ed. Horizons in Cancer Research, Volume One: Prostate Cancer. Nova Publishers, 103-118, 2004.
6. Fu Z, Zhang L, Keller ET. Immunohistochemical expression of raf kinase inhibitor protein in prostate carcinoma. In: Hayat MA ed. Handbook of Immunohistochemistry and In Situ Hybridization of Human Carcinomas. Molecular Pathology, Colorectal Carcinoma, and Prostate Carcinoma. Burlington, MA. Elsevier Academic Press, 471-479, 2005.
7. Yung R, Keller ET, Zhang J. Aging and Immunity. In: Xi H-Z, ed. Chinese Textbook of Geriatrics and Gerontology, 2nd ed. Publisher of Peoples Public Health, China. In Press.
8. Brown JM, Zhang J, Keller ET. OPG, RANKL, and RANK in cancer metastasis: expression and regulation. In: Keller ET and Chung L, Editors: The Biology of Bone Metastases. Kluwer Academic Publishers. In Press.

Abstracts (over 90, stopped keeping track at 67.)

1. Keller ET, Madewell BR. Neoplasms in the immature dog. Veterinary Cancer Society, 10th annual meeting, Auburn, Alabama October 1990.
2. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Sequential combination chemotherapy for the treatment of canine lymphoma. Veterinary Cancer Society, 11th annual meeting, Minnesota, October 1991.
3. Keller ET, Sun WH, Pugh TD, Ershler WB. Evaluation of ovariectomy and dehydroepiandrosterone sulfate administration on interleukin-6 levels and B16 melanoma growth in mice. 4th Annual Colloquium on Aging, Madison, WI, April 1993.
4. Sun WH, Keller ET, Stebler B, Ershler WB. Interleukin-6 enhanced anti-tumor immunity in mice. American Association for Cancer Research, 84th Annual Meeting, Orlando, FL, p458 May 1993.
5. Keller ET, Ershler WB. Inhibition of myeloma growth *in vitro* by interleukin-6 (IL-6) and IL-6 receptor antisense. Am. College of Veterinary Internal Med. Forum, San Francisco, CA, 1994.
6. Keller ET, Ershler WB. Inhibition of myeloma growth *in vitro* by interleukin-6 (IL-6) and IL-6 receptor antisense. Geriatric Society of America annual meeting. Atlanta, GA, 1994.
7. Keller ET, Burkholder JK, Shi F, Pugh TD, McCabe D, MacEwen EG, Malter JS, Yang N.S., Ershler WB. *In vivo* particle-mediated cytokine gene transfer into canine oral mucosa and epidermis. American Association of Cancer Research 86th annual meeting. Toronto, Canada,

- 1995.
8. Hogge GS, Burkholder JK, Culp J, Yang NS, Keller ET, MacEwen EG. Developments in gene therapy of the canine tumor model. Veterinary Cancer Society 15th annual meeting. Tucson, AZ, 1995.
 9. Keller ET, Ershler WB. Dihydrotestosterone inhibits interleukin-6 promoter activity induced by NFkB. Geriatric Society of America annual meeting. Los Angeles, CA, 1995.
 10. Keller ET, Ershler WB. Ligand-activated androgen receptor inhibits NFkB-induced transcription of the interleukin-6 promoter. Keystone Symposia: Steroid/Thyroid/Retinoic Acid Gene Family. Lake Tahoe, CA. 1996.
 11. Keller ET, Chang C, Ershler WB. Dihydrotestosterone suppresses interleukin-6 expression in LNCaP prostate cancer cells. American Association of Cancer Research 87th annual meeting. Washington DC, 1996.
 12. Keller ET, Ershler WB. Ethanol's influence on interleukin-6 production by bone cell lines: Developing a molecular model for osteoporosis. American Geriatric Society annual meeting. Chicago, IL. 1996.
 13. Stebler BA, Sun WH, Keller ET, Ershler WB. Estrogen regulation of IL-6 expression involves Ikb α . American Society for Bone and Mineral Research annual meeting. Seattle, WA. 1996.
 14. Keller ET, Chang C, Ershler WB. Dihydrotestosterone inhibits NFkB-induced transcription of the interleukin-6 promoter through maintenance of Ikb α . American Society for Bone and Mineral Research annual meeting. Seattle, WA. 1996.
 15. Keller ET, Ershler WB. Ethanol activates the interleukin-6 promoter in bone marrow stromal cells. Geriatric Society of America annual meeting. Washington, DC. 1996.
 16. Keller ET, Ershler WB. Dihydrotestosterone represses interleukin-6 promoter activation through Ikb α . First International Conference on Immunology and Aging. Bethesda, MD. 1996.
 17. Hall DM, Keller ET, Weindruch RH, Kregel KC. Caloric restriction ameliorates declining thermotolerance with age. Geriatric Society of American annual meeting. Cincinnati, OH. 1997.
 18. Keller ET, Binkley NC, Stebler BS, Kimmel DB, Hall DM, Johnston GM, Michael AG, Ershler WB. Interleukin-6 and lumbar spinal bone loss in the ovariectomized rhesus macaque. American Society for Bone and Mineral Research annual meeting. 1997.
 19. Zhang J, Johnston G, Stebler B, Hall D, Keller E. Oxidative stress transactivates the interleukin-6 promoter through phosphorylation of Ikb α . Oxidative Stress Society annual meeting. 1997.
 20. Mizokami A, Gotoh A, Yamada H, Keller ET, Chang C, Sugita A, Matsumoto T. Repression of androgen receptor expression and androgen sensitivity induced by tumor necrosis factor- α in the LNCaP prostate cancer cell line. Veterinary Cancer Society annual meeting. 1997.
 21. Yao Z, Zhang J, Keller ET. Ethanol Activates p56^{lck} Protein Tyrosine Kinase in Human Osteoblast-like Cells. American Society for Bone and Mineral Research Annual meeting. 1998.
 22. Chiu KM, Arnaud CD, Stebler B, Ju J^{3*}, Mayes D, Keller E. A Negative Relationship Between Serum Estradiol and Interleukin-6 May Regulate Bone Resorption During The Menstrual Cycle. American Society for Bone and Mineral Research annual meeting. 1998.
 23. Keller ET, Binkley NC, Stebler B, Hall DM, Johnston G, Zhang J, Ershler WB. Elevation of Bone Marrow Interleukin-6 Receptor and not Interleukin-6 is Associated with Ovariectomy-Induced Osteopenia in Rhesus Monkeys (*Macaca mulatta*). American Society for Bone and Mineral Research Annual meeting. 1998.
 24. Keller ET. Long-term estrogen replacement prevents bone loss in ovariectomized rhesus monkeys (*Macaca mulatta*). Sero Symposium on Menopause, Newport Beach, CA, 1998.
 25. Zhang J, Johnston G, Wanagat J, Keller ET. Cloning and characterization of the human interleukin-6 receptor promoter. Gerontological Society of America Annual Meeting, 1998.
 26. Keller ET, Yao Z, Zhang J. Alcohol Activates p56^{lck} Protein Tyrosine Kinase in Human Osteoblast-like Cells. American Geriatric Society, Philadelphia, PA, 1999.
 27. Zhang J, Johnston G, Wanagat J, Keller ET. Cloning and characterization of the human interleukin-6 receptor promoter. International Congress on Osteoporosis, Xian, China, 1999.
 28. Mizoami A, Gotoh A, Yamada H, Keller ET, Chang C, Matsumoto T. Tumor necrosis factor- α

- represses androgen sensitivity in the LNCaP prostate cancer cell line. American Association Cancer Research Annual Meeting, Philadelphia, PA, 1999.
29. Lin D, Keller ET. Mechanism of interleukin-6 promotion of androgen receptor function in prostate cells International Conference on Prostate Cancer Research, Iowa City, IA, 1999.
 30. Keller ET, Zhang J, Stebler B. Influence of immune factors on bone remodeling in rhesus monkeys (*Macaca mulatta*). American Society for Bone and Mineral Research Annual Meeting, 1999.
 31. Zhang J, Murtha J, Habib P, Smith P, Keller ET. Ethanol induces hepatic lipid peroxidation through interleukin-6 in mice Oxygen Society Annual Meeting, New Orleans, 1999.
 32. Keller ET, Zhang J, Johnston G, Stebler B. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFkB-inducing kinase activity. Gordon Conference on Aging. Ventura, CA, 2000.
 33. Lin D, Gopalakrishnan R, Franceschi RT, Keller ET. The bone metastatic LNCaP-derivative C4-2B prostate cancer cell line produces bone in vitro. American Association for Cancer Research Annual Meeting, San Francisco, 2000.
 34. Lin D, Mizokami A, Keller ET. Interleukin-6 Induces Androgen Receptor Function through MAPK/ERK Kinase (MEK) in Prostate Cancer Cells. American Association for Cancer Research Annual Meeting, San Francisco, 2000.
 35. Dai J, Zhang J, Lin D, Keller ET. Conditioned medium from the bone metastatic LNCaP-derivative C4-2B prostate cancer cell line induces osteoblasts to produce bone in vitro. American Association for Cancer Research Annual Meeting, San Francisco, 2000.
 36. Zhang J, Keller ET. Osteoprotegerin (OPG) inhibits osteoclastogenesis induced by prostate cancer cells in vitro. American Association for Cancer Research Annual Meeting, San Francisco, 2000.
 37. Smith PC, Dai JL, Keller ET. Anti-interleukin-6 antibody enhances chemotherapeutic-mediated inhibition of prostate cancer cell growth in vitro. American Association for Cancer Research Annual Meeting, San Francisco, 2000.
 38. Bauth JC, Ferguson KJ, Ring DL, Keller ET. The effects of exercise on interleukin-6 (IL-6) levels in the synovial fluid of osteoarthritic knees. Association of Rheumatology Health Professional Annual Meeting, Philadelphia, 2000.
 39. Morris MD, Tarnowski CP, Timlin JA, Carden A, Dreier JL, Ignelzi MA, Jr., Lin D, Keller ET. Raman Imaging as a Probe of Chemical and Biomechanical Properties of Bone Tissue. Society of Photo-Instrumentation Engineers Annual Proceedings 2000.
 40. Keller ET, Lin D, Dai J, Habib P, Zhang J, Murtha J, Smith P, Fu Z. Alcohol promotes bone loss through interleukin-6 induced osteoclastogenesis. American Society for Bone and Mineral Research Annual Meeting, Toronto, 2000.
 41. Lin D, Zhang J, Dai J, Keller ET. Alcohol induces interleukin-6 secretion from primary human osteoblasts and bone marrow stromal cells *in vitro*. American Society for Bone and Mineral Research Annual Meeting, Toronto, 2000.
 42. Zhang J, Devalaraja R, Dai J, Baragi V, Keller ET. Osteoprotegerin (OPG) and anti-interleukin-6 (IL-6) antibody inhibit osteoclastogenesis induced by prostate cancer cells in vitro. American Society for Bone and Mineral Research Annual Meeting, Toronto, 2000.
 43. Dai JL, Zhang J, Keller ET. BMP-7 is expressed in prostate carcinoma and down regulated by PTHrP in vitro. American Association for Cancer Research Annual Meeting, New Orleans, 2001.
 44. Fu Z, Keller ET. Identification of Raf kinase inhibitor protein (RKIP) as a metastasis suppressor gene in prostate cancer skeletal metastasis. American Association for Cancer Research Annual Meeting, New Orleans, 2001.
 45. Lin DL, Tarnowski CP, Zhang J, Rohn E, Patel AH, Morris MD, Keller ET. Osteotropic prostate cancer cells develop an osteoblastic phenotype, including hydroxyapatite production. American Association for Cancer Research Annual Meeting, New Orleans, 2001.
 46. Smith PS and Keller ET. Anti-Interleukin-6 Monoclonal Antibody Inhibits Prostate Cancer Growth In Vivo. American Association for Cancer Research Annual Meeting, New Orleans,

- 2001.
47. Zhang J, Dai JL, Qi Y, Strayhorn C, Lin DL, Fu Z, Keller ET. Osteoprotegerin (OPG) inhibits prostate cancer cells induced osteoclastogenesis and prevents the establishment of prostate cancer skeletal metastasis in mice. American Association for Cancer Research Annual Meeting, New Orleans, 2001.
 48. Zhang J, Dai JL, Keller ET. Anti-human OPG antibody sensitizes prostate cancer cells to TRAIL-mediated apoptosis in vitro. American Association for Cancer Research Annual Meeting, New Orleans, 2001.
 49. Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. American Society for Bone and Mineral Research Annual Meeting, Phoenix, AZ, 2001.
 50. Dai J, Zhang J, Lin D, Keller ET. Prostate cancer cells induce osteoblastogenesis through bone morphogenetic proteins. American Society for Bone and Mineral Research Annual Meeting, Phoenix, AZ, 2001.
 51. Lin D, Zhang J, Dai J, Keller. Alcohol induces interleukin-6 secretion from primary human osteoblasts and bone marrow stromal cells in vitro. American Society for Bone and Mineral Research Annual Meeting, Phoenix, AZ, 2001.
 52. B. Demiralp, H. Chen, A.J. Koh, E.T. Keller, L.K. McCauley. Anabolic effects of PTH in bone are dependent on c-fos. American Association of Dental Research, 2001.
 53. Jian Zhang, Jinlu Dai, Din-Lii Lin, and Evan T. Keller. One novel therapeutic approach for the treatment of prostate cancer skeletal metastases: targeting RANK Ligand-RANK system. AACR Cancer Targets Meeting. Florida, 2001.
 54. S Korenchuk, KJ Pienta, CR Cooper and ET Keller. Osteoblastic characteristic of a panel of xenografts derived from primary and metastatic prostate cancer lesions. AACR Cancer Targets Meeting. Florida, 2001.
 55. Jinlu Dai, Jian Zhang, and Evan T. Keller. BMP-7 Is Expressed in Prostate Carcinoma and Down Regulated by PTHrP In Vitro. AACR Cancer Targets Meeting. Florida, 2001.
 56. Jill M. Murtha and Evan T. Keller. Zebrafish Hematology and Serum Chemistry. American Association of Laboratory Animal Science Annual Meeting. Baltimore, 2001.
 57. Din-Lii Lin, Mary C. Whitney, Jinlu Dai and Evan T. Keller. Regulation of Human Bone Morphogenetic Protein-7 (hBMP-7) Expression in Human Prostate Cancer Cells. American Association of Cancer Research, San Francisco, 2002.
 58. Jinlu Dai, Jian Zhang, Din-Lii Lin, Evan T. Keller. Androgen regulation of bone morphogenetic proteins (BMPs) and its receptors (BMPRs) in human prostate cancer cells. American Association of Cancer Research, San Francisco, 2002.
 59. Jian Zhang, Jinlu Dai, Din-Lii Lin, Peter C. Smith, and Evan T. Keller. Early detection and longitudinal monitoring of prostate cancer skeletal metastases by dual-energy X-ray absorptiometry (DXA) in murine models. American Association of Cancer Research, San Francisco, 2002.
 60. Peter Smith, Evan T. Keller. Interleukin-6 and androgen receptor cofactors in prostate cancer xenografts and cell lines. American Association of Cancer Research, San Francisco, 2002.
 61. S Korenchuk, KJ Pienta, CR Cooper and ET Keller. Osteoblastic characteristics of a panel of xenografts derived from primary and metastatic prostate cancer lesions. American Association of Cancer Research, San Francisco, 2002.
 62. Zheng Fu and Evan T. Keller. Raf Kinase Inhibitor Protein (RKIP) is a Putative Prostate Cancer Metastasis Suppressor. American Association of Cancer Research, San Francisco, 2002.
 63. Corey C, Quinn JE, Zhang J, Odman A, Brown LG, Keller ET, Vessella RL. Evaluation of effects of osteoprotegerin and zoledronic acid on C4-2B prostate cancer bone metastasis. Third North American Symposium on Skeletal Complications of Malignancy, Bethesda, 2002.
 64. Jian Zhang, Zhi Yao, Yi Lu, Jinlu Dai, and Evan T. Keller. *Scutellaria baicalensis* Georgi (Huang Qin) extract diminishes growth of prostate cancer in murine bone. Third North American Symposium on Skeletal Complications of Malignancy, Bethesda, 2002.

65. Jinlu Dai, Din-Lii Lin, Mary Whitney, Jian Zhang and Evan T. Keller. Bone morphogenetic protein is regulated by androgen in an androgen-dependent prostate cancer cell line. Third North American Symposium on Skeletal Complications of Malignancy, Bethesda, 2002.
66. Corey E, Quinn JE, Odman A, Zhang J, Keller ET, Vessella RL. Characterization of C4-2 bone metastasis and its response to castration. 24rd Annual Meeting of American Society for Bone and Mineral Research, San Antonio, TX, 2002.
67. Kiefer JA, Vessella RL, Quinn JE, Odman A, Zhang J, Keller ET and Corey E, The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. 24rd Annual Meeting of American Society for Bone and Mineral Research, San Antonio, TX, 2002.